There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ICAM-1


Brief Information

Name:Intercellular adhesion molecule-1
Target Synonym:Intercellular Adhesion Molecule 1,Cell Surface Glycoprotein P3.58,Human Rhinovirus Receptor,CD54 Antigen,P3.58,CD54,BB2,Intercellular Adhesion Molecule-1,Epididymis Secretory Sperm Binding Protein,Major group rhinovirus receptor,ICAM1,ICAM-1,Intercellular
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

Human ICAM-1, Fc TagHuman ICAM-1, Fc Tag (Cat. No. IC1-H5250) ELISA bioactivity

Immobilized Human ITGALB2, His tag at 5 μg/mL (100 μL/well) can bind Human ICAM-1, Fc Tag (Cat. No. IC1-H5250) with a linear range of 0.082-1.28 μg/mL (Routinely tested).

Synonym Name



Inter-Cellular Adhesion Molecule 1 (ICAM-1) is also known as Cluster of Differentiation 54 (CD54), is a member of the immunoglobulin superfamily, and is a cell surface glycoprotein which is typically expressed in low concentrations on endothelial cells and cells of the immune system. The protein encoded by this gene is a type of intercellular adhesion molecule continuously present in low concentrations in the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFα) and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 is a ligand for LFA-1 (integrin), a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via ICAM-1/LFA-1 and then transmigrate into tissues. ICAM-1 has been implicated in subarachnoid hemorrhage (SAH). Levels of ICAM-1 are shown to be significantly elevated in patients with SAH over control subjects in many studies. ICAM-1 expressed by respiratory epithelial cells is also the binding site for rhinovirus, the causative agent of most common colds.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tocopherol acetate DSE-9912 Approved Ephynal, Aquasol E Venous Thromboembolism; Atherosclerosis; Intermittent Claudication; Thrombosis; Diabetic Retinopathy Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Bersanlimab BI-505 Phase 2 Clinical Bioinvent International Smoldering Multiple Myeloma; Multiple Myeloma Details
AIC-100 AIC-100 Phase 1 Clinical Affyimmune Therapeutics Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms Details
Coxsackievirus A21 (Viralytics) V-937; CVA-21 Phase 2 Clinical Viralytics Head and Neck Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Melanoma; Neoplasm Metastasis Details

This web search service is supported by Google Inc.